GSK R&D chief Hal Barron (left) and Vir CEO George Scangos
February 17, 2021 08:16 AM ESTUpdated 08:26 AM
Financing

Glax­o­SmithK­line bets an­oth­er $345M cash on Vir, ex­pand­ing Covid-19 part­ner­ship to flu, RSV and oth­er virus­es

Jason Mast

Editor

Af­ter Glax­o­SmithK­line and Vir signed their $250 mil­lion part­ner­ship last April, they quick­ly ran in­to a prob­lem.

The two were sup­posed to be work­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times